{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:06:35Z","timestamp":1791655595430,"version":"4.3.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,21]]},"abstract":"<jats:p>The development of targeted therapy has improved treatment outcomes for patients with non-small cell lung cancer (NSCLC). However, paronychia, a common adverse effect of targeted therapy, remains burdensome. Although conservative treatments for paronychia have been well reported in the literature, studies on the efficacy of surgical partial matricectomy for paronychia, are scarce. This study aimed to evaluate the effect of surgical partial matricectomy in targeted therapy-induced paronychia in patients with NSCLC. This retrospective cohort study included 11 patients with a total of 18 lesions on the big toes. Data on lung cancer stages, types and duration of targeted therapy, onset of paronychia, pain scale scores, conservative treatments, course of matricectomy, paronychia-free interval after matricectomy, and wound condition were collected from medical records. The Wilcoxon signed-rank test was used for analysis. The mean pain scale score after matricectomy was significantly lower than that after conservative treatments (1.00 \u00b1 0.00 vs 2.94 \u00b1 0.87; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001) and before treatment (1.00 \u00b1 0.00 vs 3.06 \u00b1 0.80; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001). The mean duration of matricectomy was significantly shorter than that of conservative treatments (3.22 \u00b1 1.00 vs 56.56 \u00b1 52.29 weeks; <jats:italic toggle=\"yes\">P &lt;<\/jats:italic> .001). Surgical partial matricectomy is an effective and enduring intervention for targeted therapy-related paronychia. It provides a shorter course of treatment, reduced pain, and improved appearance of the healed wound. Furthermore, surgical partial matricectomy could result in a better quality of life during targeted therapy than that of conservative treatments.<\/jats:p>","DOI":"10.1097\/md.0000000000031208","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T19:09:33Z","timestamp":1666638573000},"page":"e31208","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Effective and enduring surgical treatment for targeted therapy-related paronychia: A retrospective study"],"prefix":"10.1097","volume":"101","author":[{"given":"Ting-Hsuan","family":"Liu","sequence":"first","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan, Republic of China"},{"name":"Department of Surgery, Taichung Armed Forces General Hospital, Taichung City, Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"Graduate Institute of Aerospace and Undersea Medicine, National Defense Medical Center, Taipei City, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Lin","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chun","family":"Hou","sequence":"additional","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yu","family":"Lai","sequence":"additional","affiliation":[{"name":"Graduate Institute of Aerospace and Undersea Medicine, National Defense Medical Center, Taipei City, Taiwan, Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-6622","authenticated-orcid":false,"given":"Yuan-Sheng","family":"Tzeng","sequence":"additional","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"220","DOI":"10.21037\/tlcr.2018.05.06","article-title":"The epidemiology of lung cancer.","volume":"7","author":"de Groot","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","article-title":"EGFR mutations and lung cancer.","volume":"6","author":"da Cunha","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann Oncol"},{"key":"R4-20250504","first-page":"44","article-title":"Acute and chronic paronychia.","volume":"96","author":"Leggit","year":"2017","journal-title":"Am Fam Physician"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40265-015-0434-6","article-title":"Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK.","volume":"75","author":"Califano","year":"2015","journal-title":"Drugs"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2011.10.009","article-title":"The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.","volume":"67","author":"Garden","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/1346-8138.13205","article-title":"Effective treatments for paronychia caused by oncology pharmacotherapy.","volume":"43","author":"Goto","year":"2016","journal-title":"J Dermatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/0019-5154.123482","article-title":"Management of chronic paronychia.","volume":"59","author":"Relhan","year":"2014","journal-title":"Indian J Dermatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/DSS.0000000000003036","article-title":"Surgical intervention for paronychia induced by targeted anticancer therapies.","volume":"47","author":"Hanania","year":"2021","journal-title":"Dermatol Surg"},{"key":"R10-20250504","first-page":"2547","article-title":"Ingrown toenail removal.","volume":"65","author":"Zuber","year":"2002","journal-title":"Am Fam Physician"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"212613","DOI":"10.7573\/dic.212613","article-title":"Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature.","volume":"8","author":"Sollena","year":"2019","journal-title":"Drugs Context"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s00520-019-04690-8","article-title":"Are topical beta-blockers really effective \u201cIn real life\u201d for targeted therapy-induced paronychia.","volume":"27","author":"Sibaud","year":"2019","journal-title":"Support Care Cancer"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s10637-019-00825-0","article-title":"A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for cancer therapy-associated paronychia.","volume":"37","author":"Capriotti","year":"2019","journal-title":"Invest New Drugs"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3747\/co.22.2430","article-title":"Management of EGFR TKI-induced dermatologic adverse events.","volume":"22","author":"Melosky","year":"2015","journal-title":"Curr Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors.","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/jamadermatol.2015.4448","article-title":"Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non\u2013small cell lung cancer.","volume":"152","author":"Chen","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1634\/theoncologist.2017-0582","article-title":"Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer.","volume":"23","author":"Chu","year":"2018","journal-title":"Oncologist"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000490177","article-title":"Relationship between paronychia and drug concentrations of epidermal growth factor receptor tyrosine kinase inhibitors.","volume":"95","author":"Masago","year":"2018","journal-title":"Oncology"},{"key":"R19-20250504","first-page":"1113","article-title":"Acute and chronic paronychia.","volume":"63","author":"Rockwell","year":"2001","journal-title":"Am Fam Physician"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2020.06.010","article-title":"Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: an assessment of topical timolol and the need for multiple medical and procedural therapies.","volume":"84","author":"Olamiju","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e14174","DOI":"10.1111\/dth.14174","article-title":"Intralesional steroid treatment for the intermediate stage of retronychia: a pilot study.","volume":"33","author":"Alessandrini","year":"2020","journal-title":"Dermatol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:41:42Z","timestamp":1746333702000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":21,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031208","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}